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Abstract
Background: Visceral Leishmaniasis (VL) is endemic in 88 countries, in areas of relatively low incidence with a
relevant proportion of immune suppressed patients clinical presentation, diagnosis and management may present
difficulties and pitfalls.
Methods: Demographic data, clinical, laboratory features and therapeutic findings were recorded in patients
identified by a regional VL disease registry from January 2007 to December 2010.
Results: A total of 55 patients (36 adults mean age 48.7 years, 19 children median age 37.5 months) were observed
presenting with 65 episodes. All childen were immunocompetent, whereas adults affected by VL included both
immunocompetent (n°17) and immunesuppressed (n°19) patients. The clinical presentation was homogeneous in
children with predominance of fever and hepato-splenomegaly. A wider spectrum of clinical presentations was
observed in immunocompromised adults. Bone marrow detection of intracellular parasites (Giemsa staining) and
serology (IFAT) were the most frequently used diagnostic tools. In addition, detection of urinary antigen was used
in adult patients with good specificity (90%). Liposomal amphotericin B was the most frequently prescribed first line
drug (98.2% of cases) with 100% clinical cure. VL relapses (n°10) represented a crucial finding: they occurred only in
adult patients, mainly in immunocompromised patients (40% of HIV, 22% of non-HIV immunocompromised
patients, 5,9% of immunocompetent patients). Furthermore, three deaths with VL were reported, all occurring in
relapsing immunocompromised patients accounting for a still high overall mortality in this group (15.8%).
Conclusions: The wide spectrum of clinical presentation in immunesuppresed patients and high recurrence rates
still represent a clinical challenge accounting for high mortality. Early clinical identification and satisfactory
treatment performance with liposomal amphotericin B are confirmed in areas with low-level endemicity and good
clinical standards. VL needs continuing attention in endemic areas where increasing numbers of
immunocompromised patients at risk are dwelling.
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Background
Leishmaniasis is a complex of mammalian diseases
caused by protozoans classified as Leishmania species
(Order:kinetoplastida Family:trypanosomatidae) [1,2]. Nat-
ural transmission may be zoonotic or anthroponotic,
and occurs through the bite of a phlebotomine sandfly
species (order Diptera) of the genus Phlebotomus (old
world) and Lutzomyia (new world) [3,4] with the do-
mestic dog as the main reservoir for visceral disease in
the Mediterranean basin but in other hyperendemic
areas (or instance Sudan or India) humans act as the
main reservoir.
Leishmaniasis is endemic to 88 countries, including
Europe. In southern Europe the majority of reported
cases are due to zoonotic visceral leishmaniasis (VL),
which is fatal when untreated. The more benign cutane-
ous leishmaniasis (CL) is also present in this area. Inci-
dence of leishmaniasis in humans is relatively low,
ranging from 0.2 × 10-6 to 0.49 × 10-6 (85.3 × 10-6 includ-
ing Turkey). This estimate corresponds to 700 reported
new cases per year in Southern Europe (3,950/yr if
Turkey is included). The disease is spreading north be-
cause of several risk factors, climate being only one.
Changes to the environment, population movements,
dog and vector mobility may contribute to the spread.
In the Netherlands Leishmania has been introduced by
dogs returning from military missions, albeit without trans-
mission due to lack of vector [5]. A pattern of northward
spread and notification of autochtonous VL due to vector
diffusion has been recorded in northern Italy [6,7] and
southern Germany [8,9].
In addition to this developing epidemiological pattern,
new clinical presentations have been recently described
in developed areas including isolated lymphoadenopathy
sustained by Leishmania infantum [10,11] or active chronic
visceral leishmaniasis [12]. In this context, increasing num-
bers of patients with secondary immunodeficiency due to
medication including immunosuppressive treatment, solid
organ or bone marrow transplantation and chemotherapy
in endemic areas may determine an increase in receptive
hosts and may represent diagnostic and management diffi-
culties [13].
To address these issues, a Regional Disease Register
was established encompassing all Infectious Disease
Units in a coastal area in Northern Italy. The Register
has the primary aim of monitoring prospectively the
diagnostic, clinical and therapeutic approach to VL
in the region, and to identify possible critical areas
where changes in perception and management might
be required.
Aim of the present analysis was to evaluate and re-
port on clinical presentation, diagnostic tools and treat-




The Ligurian Registry for Visceral Leishmaniasis (Registro
Ligure Leishmaniosi viscerale, RiLLeVi) was established at
the end of 2006 and began to record data from January
1st 2007. It is composed of 7 Infectious Diseases Hospital
units in the administrative region Liguria (approx.1.5 M
inhabitants). The Infectious Diseases (ID) Units are lo-
cated in Sanremo, Pietra Ligure, Savona, Genova (3 Units),
and La Spezia. Patients are referred from local Accidents
and Emergency (A&E) departments, general practitioners
or as outpatients. Workup as inpatients is recorded and
collected for those with a diagnosis of VL. Twice a year,
locally collected data are transmitted to the coordinators,
and placed on a database. History, clinical evaluation diag-
nostic procedures and treatment schedules are collected.
Cases and results are examined periodically and discussed
during an annual meeting.
Each center independently cared for patients according
to optimized baseline standards for the diagnosis and man-
agement of infectious diseases.
Ethical Committee approval was sought and obtained
by the coordinating center for the observational data
gathering. All patients provided informed consent for
data gathering.
Diagnostic procedures
Diagnostic criteria for leishmaniasis fulfilled WHO cri-
teria for both clinical and laboratory definition in all the
patients including immunocompetent adults, immuno-
deficient adults and children (main symptoms and posi-
tive parasitology and serology) [14].
Specific tests for the diagnosis of Leishmania infec-
tion included: microscopic demonstration of Leishmania
amastigotes on Giemsa stained smears of bone mar-
row aspirates, serology by immunofluorescence (IFAT,
Biomerieux, France) and urinary antigens (Katex, Kalon
Diagnostics UK). Polymerase chain reaction (PCR) for the
identification in blood or bone marrow of Leishmania
DNA sequences in the kinetoplast region was performed
as described elsewhere [15].
IFAT and Urinary antigen were performed at the
Sanremo center. Cut-off values for positive IFAT results
were 1:80 serum dilutions.
Patient data, clinical presentation and treatment
According to registry requirements, epidemiological clin-
ical and laboratory data were recorded for each patient
each time an episode of VL was identified, including sex,
age, town of residence, HIV infection, neoplasia or admin-
istration of immunosuppressive regimens, full haemato-
logical assessment, total protein, protein electrophoresis.
Clinical evaluation of hepato- and splenomegaly were de-
fined and graded according to clinical guidelines [16],
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anemia [17], neutropenia (<1500/μl) [18] and throm-
bocytopenia (<150,000/μl) [19] were defined as described.
In HIV infected patients peripheral CD4+ T-cell counts,
HIV viral load and drug history were recorded.
The main presenting aspects of the first clinical epi-
sode that led to VL diagnosis after admission to the ID
unit was characterized and described in order to allow
for possible heterogeneity of underlying clinical condi-
tions and different patient age.
Treatment drugs, regimens, administration schedules
and adverse events of grade 2 or higher associated with
treatment were recorded.
No distinction between VL relapse and reinfection was
possible. Patients presenting with recurrent episodes
were therefore defined as “recurring” or “relapse” with-
out distinction between relapse and reinfection.
Statistical analysis
Categorical data were summarized as number and per-
centage of subjects, continuous data as mean, standard
deviation and range. Comparisons between laboratory
values were performed with the Kruskal-Wallis test for
independent samples. Mann–Whitney, Wilcoxon
(Breslow) and Chi-square tests were applied where
needed. The time to relapse were evaluated with Log-
rank test for equality of survivor functions and Wilcoxon
test for equality of survivor functions. Statistical signifi-
cance was defined as a P-value of less than 0.05 (two-
sided). All statistical analyses were performed using the
STATA 11.0 Software (StataCorp LP, College Station,
TX) and SPSS 13,0(SPSS Inc, Chicago, IL). Statistical
significance was defined as a P-value of less than 0.05.
Results
Epidemiology of identified cases
Information on patients with confirmed VL diagnosis
was collected from 01/01/2007 to 31/12/2010. All the
seven Infectious diseases Units from the region were in-
volved and participated. Five units actively reported con-
firmed VL cases. Of five centers one is in a tertiary care
pediatric Institute (G.Gaslini) and reported exclusively
pediatric cases. Two units did not observe VL cases in
their area. Figure 1 indicates the area of origin where pa-
tients were living.
Figure 1 Map showing area of residency of patients in Liguria region and location within Italy and Europe. Signs show area of residency
and hospital Infectious Diseases Unit where seen as inpatients. Star: children seen at Gaslini Hospital, Cross: patients seen at Sanremo Unit,
Triangles: patients seen at Pietra Ligure Unit, Circles: patients seen at the Savona Unit, Greyed Squares: Patients seen at the Galliera Hospital Unit,
Open Square: patients seen at the IRCCS S. Martino Hospital Unit.
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Sixty-five episodes of VL were recorded in 55 patients
(36 adults, 19 children) (Table 1). Up to three VL relapses
occurred in 7 (12,5%) adult patients requiring additional
evaluation and treatment as inpatients.
The mean age of pediatric patients (7 M, 12 F) was
37,5 months (range:11–155), and adult patients (21 M,
15 F) had a mean age of 48,7 yrs (range 21–87). All pa-
tients stably lived in the Liguria coastal area, with the
exception of three children being referred from other
Italian endemic areas.
All the children were immunocompetent, as defined by
absence of primary immunodeficiency, autoimmunity,
cancer, HIV infection or previous administration of poten-
tially immunosuppressive treatment. The 36 adult patients
were subdivided into two groups according to their im-
mune status. Of these, 17 (47%) were immunocompetent
(ICC), and 19 (53%) were immunocompromised (ISS).
HIV-1 infection was the dominant cause of immunosup-
pression (10 pts, 59%), while the other 9 patients (41%)
had variable underlying diseases requiring immunosup-
pressive treatment including steroid therapy (6pts), chemo-
therapy in multiple myeloma, rituximab chemotherapy for
Non Hodgkin Lymphoma and cyclophosphamide-steroid
treatment in a patient with pseudohemophilia and anti-
factor VIII Ab (1 case each). Multiple episodes of VL were
recorded in some patients over the study period. Therefore,
the present evaluation takes into account VL episodes
where indicated.
Clinical features and presentation
Overall clinical features recorded among all patients are
summarized in Table 2. The main presenting clinical pic-
ture, defined as the clinical/laboratory values that led to
referral to the Infecitous Diseases Units are indicated in
Table 3. All the 19 children with VL were immunocompe-
tent as opposed to adults, who had an underlying cause of
immunosuppression in 52% (19/36) of the instances (Chi
square, p = 0.001). Children were all febrile at presenta-
tion, while 4/36 (10%) of adults were afebrile and reported
no fever in preceding days. The most frequently observed
clinical presentation was fever associated with liver and
spleen enlargement. This presentation was more frequent
in children (100%) compared to adults (54.3%), (Chi-
square p = 0.001).
Among the 28 VL episodes in immunocompromised
patients, fever (>37,5°C) and peripheral cytopenia (8 pts)
was the second most frequently recorded clinical presen-
tation after fever and hepato- splenomegaly, and was
unique to immunocompromised compared to immuno-
competent patients (8/28pts vs.0/28 pts, respectively, Chi-
square p = 0,003). Fever and hypergammaglobulinemia
were recorded on admission only in adult immunocompe-
tent patients, while reduced cytopenia was observed only
in immunocompromised adults.
When considering haemoglobin levels, significant differ-
ences emerged among the three patient groups (9.69 ±
1.88, 10.11 ± 2.28, 8.02 ± 0.90 g/dl) in immunocompro-
mised adults, immunocompetent adults, children respec-
tively). Overall, mean Hb concentration was 8.85 gr/dl
(6,60-15 gr/dl) with significant differences and lowest
mean values in children, (p = 0.001, Kruskall-Wallis).
Average white blood cell (2661 ± 952 3842 ± 3122,
4353 ± 2170/μl, in immunocompromised adults, immuno-
competent adults, children respectively) and neutrophil
counts (1766 ± 767 2262 ± 2420, 1091 ± 645/μl in immuno-
compromised adults, immunocompetent adults, children
respectively) were below the lower laboratory reference
limits in all patient groups. Significant differences were
present for both leukocyte (p = 0.032 Kruskall-Wallis) and
neutrophil counts (p = 0.017, Kruskall-Wallis), with chil-
dren displaying lowest neutrophil counts, and immuno-
compromised patients lowest leukocyte counts.
In addition, mean total blood protein (7.39 ± 1.24,
7.76 ± 1.16, 7.68 ± 0.92 g/dl, in immunocompromised
adults, immunocompetent adults, children respectively)
and albumin (2.88 ± 0.68 3.28 ± 0.60 2.98 ± 0.56 g/dl, in
immunocompromised adults, immunocompetent adults,
children respectively) values were similar among the
three groups of patients, while γ-globulin concentrations
(3.00 ± 1.02, 2.46 ± 1.12, 1.72 ± 0.49 g/dl in immunocom-
promised adults, immunocompetent adults, children re-
spectively) were consistently different in adults and
children with lowest values in pediatric patients (p < 0,0001,
Kruskall-Wallis).
Table 1 VL cases, first episodes and recurrences
Cause for
immunocompromise
Patients Total episodes Recurring episodes
Immunocompetent 17 18 1
Immunocompromised 19 28 9
HIV 10 15 5
non-HIV 9 13 4
Subtotal 36 46 10
Children 19 19 0
Total 55 65 10
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VL diagnostic methods
Among the tools used for VL diagnosis, Giemsa staining
and microscopic examination of bone marrow samples
was the most frequently used technique (48/65 episodes,
73%). Microscopic examination of bone marrow aspi-
rates was more frequently employed in children (18/19
episodes, 94,7%) compared to adults (30/46 episodes,
62,1%) Among adults, bone marrow aspiration was per-
formed more frequently in VL episodes in ICC (15/18)
than in ISS (16/28). No differences in diagnostic procedure
employment were statistically significant.
Table 4 reports for each patient group the comparative
methods employed and its performance expressed as the
proportion of patients with a diagnosis of Leihmaniosis
at first observation correctly identified by a given diag-
nostic procedure. The identification of anti-Leishmania
serum antibodies by immunofluorescence (IFAT) is a re-
liable, non-invasive diagnostic tool. Here, serology for
Leishmania was carried out in 60/65 VL episodes (92,3%).
Overall, anti-Leishmania antibodies were detected in 14/
15 (93%) of episodes occurring in children and in 43 of 45
(95,6%) VL episodes recorded among adults with similar
rates of positivity in immunocompetent and immunocom-
promised patients.
Identification of Leishmania urinary antigen was cen-
tralized, introduced as a diagnostic support and offered
to the other centers within the registry for suspected
cases. Overall, it was employed in 30/46 (65%) adult epi-
sodes, (55.6% of immunocompetent and 71,4% of im-
munocompromised adults) while none of the children
was tested for the presence of urinary antigens. Urinary
Leishmania antigen was detected in 27/30 (90%) of epi-
sodes (8/10(80%) in Immunocompetent and 19/20 (95%)
in immunesuppresed patients.
Polymerase chain reaction (PCR) for Leishmania-specific
sequences in bone marrow aspirates was performed at a
National Reference Laboratory (Dr. L. Gradoni, Istituto
Superiore di Sanità, Rome) in 11 patients with 100% posi-
tive results, and on peripheral blood of 9 additional pa-
tients with positive results in 6 cases (66,7%) [15].
In children, microscopic detection on bone marrow
samples was positive in 15/18 (83,3%).
Treatment courses and VL relapse episodes
Liposomal amphotericin is the drug of choice for the
treatment of VL in Europe [20-22]. Indeed, during the
observation period of the registry 62 (95%) episodes of
VL were treated with liposomal amphotericin B with
amphotericin B lipid emulsion being used in one in-
stance. Miltefosine was administered to 2 patients dur-
ing a VL relapse episode.
Table 2 Symptoms and blood laboratory data in patients with VL, stratified according to risk group
Children (19pts) ICC (17pts) ISS HIV+ (10pts) ISS HIV-(9pts)
Constitutional Symptoms 19(100%) 15 (88.2%) 10 (100%) 9 (100%)
Hepato + Splenomegaly 19 (100) 11 (65%) 8 (8%) 6 (66%)
Lymphoadenopathy 0 1 (6%) 0 0
Other symptoms 0 0 2 (20%) 1 (1%)
Haematological data 18 (95%) 17(100%) 10(100%) 9(100%)
–Anemia 12(63.2%) 10(58.8%) 10(100%) 6(66.6%)
–Leukopenia 15(78.9%) 8(47.1%) 8(80%) 0
–Trombocytopenia 2(11.8%) 1(10%) 0
–Pancytopenia 0 6(60%) 2(33.3%)
-Hypergammaglobulinemia 15((78.9%) 5(29.4%) 8(80%) 6(66.6%)
Table 3 Clinical presentation on admission according to patient risk group
Patient group F + S F + L L F + P F + H T Other
Children (19) 19 (100%) 0 0 0 0 0 0
Adults (46) 25 (54,3%) 2 (4,3%) 2 (4,3%) 8 (17,4%) 4 (8,7%) 2 (4,3%) 3 (6,5%)
ICC(18) 11 (61,1%) 0 2 0 4 0 1
IDD (28) 14 (50%) 2 (7,1%) 0 8 (28,6%) 0 2 (7,1%) 2 (7,1%)
HIV + (15) 8 (53,3%) 2 (13,3%) 0 2 (13,3%) 0 2 (13,3%) 1 (6,6%)
non-HIV (13) 6 (46,15%) 0 0 6 (46,15%) 0 0 1 (6,7%)
Other: Gastritis, and Haemophagocytic syndrome, 1 presentation each.
F fever, S splenomegaly, L lymphadenopathy, P pancytopenia, H hyper-gammaglobulinemia, T thrombocytopenia.
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Overall, there was a good homogeneity of prescription
schedules. Three different schedules of liposomal am-
photericin B administration were recorded: 3 mg/kg
“short” regimen in children and ICC adults (days 1➔ 5,
day 14,day 21;36 episodes), a 3 mg/kg “extended” regi-
men in ISS adults (days 1➔5,10,17,24,31,38; 10 episodes)
and a 4 mg/kg “extended” regimen in 16 episodes of VL
occurring in ISS adults. Amphotericin B lipid emulsion
was prescribed at 3 mg/kg according to a “short” regimen.
Miltefosine was administered at 2.5 mg/kg according to
registration studies [23] for successful full 28 days courses
in two immunocompromised adults following clinical fail-
ure on liposomal Amphotericin B or VL relapse.
When analyzing VL recurrent episodes, these were ob-
served in 5/10 (40%) HIV+, 4/9 (22.2%) non-HIV immuno-
compromised and 1/17 (5,9%) immunocompetent patients.
Ten episodes of VL recurrence were registered among 46
episodes diagnosed in infected adult patients (21,7%). No
VL relapse was observed during follow up of the children.
Of the 10 recurring episodes, 9 occurred in immunocom-
promised adults after a median of 331 days from the first
VL episode, and one was observed in an otherwise im-
munocompetent adult after 143 days. This difference was
significant by Kaplan-Meyer analysis (p < 0.0001) (Figure 2
panel A). Among VL recurring episodes, there was no dif-
ference in the frequency between HIV-infected and non-
HIV infected immunocompromised patients (Figure 2
panel B), and time to recurrence was not significantly differ-
ent (345 days vs. 314 days). Clinical features at relapse were
similar to those detected at the first presentation for each
patient with at least one recurrence of VL.
None of the immunocompromised patients subsequently
presenting with a second VL episode were on secondary
prophylaxis. Among HIV infected patients, mean CD4+ cell
counts and viremia at first VL diagnosis were 135 ± 101/μl
and 6,974 × 104 cp/ml (range: 0–2,8 × 105), respectively. In
3/10 patients CD4+ cell counts were >200 μl at diagnosis
with 2 of these 3 cases recording CD4+ cells >250÷μl. No
significant CD4+ cell count differences were present among
those who would not recur compared to those for whom a
VL recurrence was observed (148 ± 129/μl vs. 115 ± 40/μl,
respectively) Among the 5 VL relapses in HIV infected pa-
tients, CD4+ cell counts at recurrence were 152 ± 89,39/μl
(Mean ±DS). CD4 cell numbers at VL recurrence were
not different compared to those for the patients at baseline
(1st VL diagnosis). Among the 10 HIV patients with VL ep-
isodes, 4 were not on HAART and VL represented their
first opportunistic infection, albeit non AIDS-defining.
Among the other 6 patients a failing HAART regimen with
persistent viremia >50 cp/ml was recorded in 4 cases.
Mortality in this cohort was assessed for all patients
during the follow up period as any incident case of death
within the cohort included in the registry during the ob-
servation period. Overall, 3 deaths were recorded among
the 55 patients (5.5%). Patients who died were all im-
munocompromised (3 of 19, 15,8%). Two patients died
with leishmaniasis but cause of death was attributed to
disseminated Mycobacterium Avium-intracellulare Com-
plex in 1 case and to complications of carcinoma of the
lungs (1 patient). One patient died due to Leishmaniasis.
Of these 3 patients (2 HIV+, 1 non-HIV), 2 had experi-
enced VL relapse. Mortality was high among relapsing
patients (2 of 5 relapsing HIV + patients, 1 of 4 relapsing
non-HIV immunocompromised patients).
Thus, treatment regimens were quite homogeneous
during the survey. A high rate of VL recurrence in adult
patients was observed in both HIV-infected and in HIV-
uninfected immunocompromised patients. High mortal-
ity rates are associated to VL relapse and poor clinical
condition.
Discussion
Visceral leishmaniasis is a neglected disease with frequent
underdiagnosis and underreporting in both developing and
developed areas [24,25]. Results of this registry/surveillance
program points towards a changing spectrum of disease
presentation in adult patients, and high rates of relapse in
immunocompromised adults, both HIV-infected and HIV-
uninfected. Immunocompromised patients represented
53% of adult patients with VL in this study. The clinical
presentation in these patients was classical (i.e.: fever, he-
patomegaly, splenomegaly) in only 50% of instances. The
Table 4 Relative performance of Diagnostic tests for Leishmaniasis
I.F. Serology Microscopy (BM) Urinary Ag PCR - P. Blood PCR-Bone Marrow
Group (n°) POS NEG ND POS NEG ND POS NEG ND POS NEG ND POS NEG ND
Children(19) 14 (73,6%) 1 (5.3%) 4 17 (89.5%) 1 (5.3%) 1 0 0 19 1 (5.3%) 0 18 8 (42.1%) 0 11
Adults(36) 33(91,7%) 2(5,6%) 1 19(52,8%) 4(11,1%) 13 25(69,5%) 3(8.3%) 8 5(13,9%) 2(5,6%) 29 3(8,4%) 0 33
ICC(17) 15(88,2%) 1(6,7%) 1 11(64,7%) 4(23,5%) 2 8(47.0%) 2(11,8%) 7 3(17,6%) 0 14 0 0 17
ISS(19) 18(94,7%) 1(5,3%) 0 9(47,4%) 2(10,5%) 8 10(52,6%) 1(5,3%) 8 2(10,6%) 2(10,6%) 15 3(15,8%) 0 16
HIV(10) 10(100%) 0 0 3(30%) 1(10.0%) 6 7(70.0%) 0 3 2(20.0%) 1(10.0%) 7 2(20.0%) 0 8
Non-HIV(9) 8(88,9%) 1(11,1%) 0 6(66,7%) 1(11,1%) 2 3(33,3%) 1(11,1%) 5 0 1(11,1%) 8 1(11,1%) 0 8
Numbers in brackets refer to the proportion (%) of patients actually evaluated by a given diagnostic method. ICC immunocompetent, ISS immunocompromised,
HIV HIV infected. HIV and non-HIV are subgroups of the ISS patients.
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apparent change in disease spectrum was thus due to a
shift in the composition of patient groups presenting with
VL disease, with a high proportion of immunocompro-
mised patients being notified to the registry. In addition,
the relevant number of relapses observed may be regarded
as a change from what we are used to observe or from
what is usually described/expected. These features are
likely to be increasingly observed with the persistence of
Leishmania transmission in endemic areas, with its spread
northwards (6,7) and with the increase in the prevalence of
immunocompromised patients (both HIV + and HIV-) in
these areas.
Of the 55 enrolled patients in the present study, 34% were
otherwise immunocompetent HIV-uninfected children. VL
clinical presentation features were quite homogeneous in
pediatric patients and did not differ from those previously
reported from the mediterranean basin in Italy [26] and
southern France [27], with fever and hepatosplenomegaly
being the main presenting complaint. Compared to those
reported from Sicily [26] children in the present report
were older (3 vs. 1.7 yrs) and had neither concomitant in-
fections/diseases, nor cutaneous manifestations of visceral
invasive disease. None of the children was diagnosed with
advanced VL features including ascites or hemorrage, nor
presented with diarrhea or bronchopneumonia as recently
reported in a high proportion (27% and 84% respectively)
of pediatric cases in a retrospective study in Albania
[28]. These differences could reflect clinical alertness of
the pediatric regional network and overall early referral
to the main regional pediatric institute with high clinical
Figure 2 Kaplan-Meyer analysis of Relapse-free time after the first Visceral Leishmaniasis event among observed patients. Panel A. Time
to relapse (in days) in Immunocompetent(ICC)vs. Immunocompromised (ISS) pts. Log-rank test for equality of survivor functions (chi2 = 0.0002);
Wilcoxon (Breslow) test for equality of survivor functions (Pr > chi2 =0.0004). Panel B. Time to relapse (in days) in Immunesuppresed pts.: HIV + vs. other
causes (Others). Log-rank test for equality of survivor functions (chi2 = n.s.); Wilcoxon (Breslow) test for equality of survivor functions (Pr > chi2 = n.s.).
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standards. On the contrary, adult patients reported to the
registry had a wide variability of clinical presentation. Sig-
nificantly increased proportions of fever and bone marrow
defects were observed in immunocompromised patients in
the absence of hypergammaglobulinemia. This variable pat-
tern of VL presentation in adult patients, together with the
fragmentation of incident cases over different centers
(see map), may represent a challenge for initial diagnostic
workup in areas of low endemicity, higher prevalence of
immunosupressed patients, or in areas where VL is pres-
ently spreading [6-8].
The development and use of non-invasive and robust
diagnostic tools in addition to IFAT could be of help in the
diagnosis of suspected VL cases without requiring invasive
procedures including bone marrow or splenic aspirate. In
the present work, urinary antigen detection was used exclu-
sively in adult patients. In this setting, its sensitivity was
good and compared well with serology (IFAT) both in im-
munocompetent and in immunesuppresed adults. This
finding is in line and confirms previous data where specifi-
city was 96% with sensitivity of 85.7 and 100% [29,30].
Thus, in areas of focal scattered incident cases with a
mostly vector-borne low endemicity, or in developing areas
of the world, the addition of leishmania urinary antigen
detection to IFAT may avoid the need to adopt more costly
or invasive techniques (i.e. leishmania PCR-DNA detection
and bone marrow aspiration, respectively) that may be
available only in referral centers. Another rapid serology
test, the k39 dipstick test [31], has proven to be highly
specicfic and sensitive for the diagnosis of leishmaniasis.
Due to its unavailability for routine clinical use, we could
not compare the performance of urinary antigen and k39
dipstick tests.
VL recurrence in HIV patients is a well characterized
problem and the main clinical predictors of this event
include: absence of a CD4+ increase at follow up, lack of
secondary prophylaxis and CD4+ cell counts <100/μl at
the time of primary VL diagnosis [32]. We here observed
some differences compared to previous reports [33,34].
Most of our HIV coinfected patients were either off
HAART or in a failing HAART regimen at VL diagnosis
(8/10) and relapsers had either no rise in CD4+ cells or
were not administered secondary prophylaxis. However,
most of them had CD4+ cell counts well above 100/μl,
and in 30% of the cases >200/μl. In addition, multiple re-
lapses were recorded in a virologically suppressed pa-
tient, and one relapse was observed in a non-HIV
immunocompetent patient. Thus, although HAART has
radically changed the epidemiology and incidence of VL
in HIV patients [35,36], in the presence of prolonged or
failing HAART, other factors may be associated to the ap-
pearance of VL at higher CD4+ cell counts. HIV-
Leishmania coinfection in these patients may reproduce a
vicious cycle leading to persistent immune derangement
and paradoxical persistence of low CD4+ cell counts and
parasitemia despite HAART and liposomal amphotericin
B administration [37,38]. In this context, the good sensi-
tivity of urinary leishmania antigen detection observed in
this study, could represent a useful tool to monitor poten-
tial VL relapse/persistence. Indeed, while monitoring post-
treatment cure in a series of 130 patients, detection of
urine parasite antigens was not associated with clinical
disease in 54% of patients [29] and could represent clinical
latency with parasite persistence. Its use for monitoring
immunocompromised patients after completion of treat-
ment could therefore provide additional support in the
management of VL patients with secondary prophylaxis
regimens, and help identify those at risk of relapse. In this
context, also the k39 dipstick may identify persistent
antigenemia that may be interpreted as asymptomatic in-
fection [39]. The present work was limited by the impossi-
bility to discriminate between Leishmania reinfection or
relapse therefore the possibility of new infections among
immunocompromised patients could not be ruled out.
Given previous experience in this area [33,34], however, it
is likely that the majority of relapses observed among im-
munocompromised patients were “true relapses” rather
than reinfections.
Larger patient numbers and prospective studies may
be suited to confirm the presently observed changing
pattern and high mortality of patients with VL relapses
due to the increasing prevalence of immunocompro-
mised hosts and still incomplete control of VL through
secondary prophylaxis.
Conclusion
In conclusion the present data provide a picture of what
is actually occurring in everyday clinical practice and
may offer a “snapshot” on the often underreported or
underestimated cases of VL relapse that may need more
intensive clinical efforts at improving secondary VL
prophylaxis, VL monitoring using leishmania antigen tests
(urinary or serum), and HAART intensification to im-
prove patient survival.
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